title: Journal Club: Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome.
abstract: Transient headache exacerbation during IV dihydroergotamine (DHE) therapy of migraine may prompt clinicians to prematurely discontinue DHE therapy, potentially depriving patients of the full benefit of DHE infusion. In a recent Neurology® article, Eller et al. evaluated whether or not worsening headache during DHE infusion was associated with suboptimal medium-term headache outcomes.
authors.affiliation: From the Stanford Headache and Facial Pain Program, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, CA. ywoldeam@stanford.edu.
authors.forename: Yohannes W
authors.initials: YW
authors.lastname: Woldeamanuel
authors.affiliation: From the Stanford Headache and Facial Pain Program, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, CA.
authors.forename: Meabh
authors.initials: M
authors.lastname: O'Hare
authors.affiliation: From the Stanford Headache and Facial Pain Program, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, CA.
authors.forename: Danielle D
authors.initials: DD
authors.lastname: DeSouza
authors.affiliation: From the Stanford Headache and Facial Pain Program, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, CA.
authors.forename: Robert P
authors.initials: RP
authors.lastname: Cowan
mesh_terms: D018712:Analgesics, Non-Narcotic; D004087:Dihydroergotamine; D006261:Headache; D006801:Humans; D008881:Migraine Disorders
chemical_list: D018712:Analgesics, Non-Narcotic; D004087:Dihydroergotamine